

Deep Phenotyping of Alzheimer's Disease Leveraging Electronic Medical Records Identifies Sex-Specific Clinical Associations

Supplementary Information

Alice S. Tang^{1,2,3*}, Tomiko Oskotsky^{1,4}, Shreyas Havaldar⁵, William G. Mantyh⁶, Mesude Bicak^{5,7}, Caroline Warly Solsberg^{8,9,10}, Sarah Woldemariam¹, Billy Zeng³, Zicheng Hu¹, Boris Oskotsky¹, Dena Dubal⁹, Isabel E. Allen¹⁰, Benjamin S. Glicksberg^{5,7}, Marina Sirota^{1,4*}

Supplementary Tables

	Count	Age	Death Status	Race	
Alzheimer's Cohort	6,612	86.4 90 (83-91)	Alive: 6714 (76.3%) Deceased: 2090 (23.7%)	White/Caucasian: 5462 (64.0%) Asian: 879 (10.3%) Black/African American: 586 (6.9%) Hawaiian/Pacific Islander: 452 (5.3%)	American Native: 9 (.1%) Other: 743 (8.7%) Unknown/Declined: 802 (4.7%)
Males	2,382 (36.0%)	85.7 90 (84-91)	Alive: 1778 (74.6%) Deceased: 604 (25.4%)	White/Caucasian: 1570 (66.8%) Asian: 254 (10.8%) Black/African American: 128 (5.4%) Hawaiian/Pacific Islander: 117 (5.0%)	Other: 209 (8.9%) Unknown/Declined: 72 (3.1%)
Females	4,223 (63.9%)	86.8 90 (82-91)	Alive: 3084 (73%) Deceased: 1139 (27%)	White/Caucasian: 2525 (60.5%) Asian: 497 (11.9%) Black/African American: 393 (9.4%) Hawaiian/Pacific Islander: 217 (5.2%)	American Native: 8 (0.2%) Other: 404 (9.7%) Unknown/Declined: 130 (3.1%)
Other or Unknown	7 (0.10%)	90.7 91 (90.5-91)	Alive: 7 (100%)	White/Caucasian: 6 (85.7%) Unknown/Declined: 1 (14.3%)	
Control Cohort	13,224	86.2 90 (83 – 91)	Alive: 13432 (76.3%) Deceased: 4176 (23.7%)	White/Caucasian: 10924 (64.0%) Asian: 1759 (10.3%) Black/African American: 1172 (6.9%) Hawaiian/Pacific Islander: 904 (5.3%)	American Native: 18 (.1%) Other: 1487 (8.7%) Unknown/Declined: 802 (4.7%)
Males	4,674 (35.3%)	85.8 90 (82-91)	Alive: 3248 (69.5%) Deceased: 1426 (30.5%)	White/Caucasian: 3076 (66.8%) Asian: 490 (10.7%) Black/African American: 277 (6.0%) Hawaiian/Pacific Islander: 222 (4.8%)	American Native: 5 (.1%) Other: 384 (8.3%) Unknown/Declined: 247 (3.2%)
Females	8,539 (64.6%)	86.5 90 (84-91)	Alive: 6253 (73.2%) Deceased: 2286 (26.8%)	White/Caucasian: 5225 (61.9%) Asian: 1024 (12.1%) Black/African American: 768 (9.1%) Hawaiian/Pacific Islander: 387 (4.6%)	American Native: 11 (.1%) Other: 783 (9.3%) Unknown/Declined: 246 (2.9%)
Other or Unknown	11 (0.10%)	90.2 90 (90-91)	Alive: 10 (90.9%) Deceased: 1 (9.1%)	White/Caucasian: 1 (11.1%) Other: 3 (33.3%)	Unknown/Declined: 5 (55.6%)

Supplementary Table 1. Patient Demographics with Encounter Thresholds and Controlling.

Distribution of sex, estimated age, death status, and first race among Alzheimer's and control cohorts. These cohorts are thresholded on more than 10 encounters, and over a year representation in the EMR. Patients are matched at a 1:2 Alzheimer to control ratio with the demographics shown in the table. Estimated age shows mean and median (25%ile - 75%ile).

AD (Alzheimer's disease) (HCC)	Dementia of the Alzheimer's type, with late onset, with depressive mood (HCC)
Alzheimer disease (HCC)	Dementia, Alzheimer's, with behavior disturbance (HCC)
Alzheimer disease type 3 (HCC)	Early onset Alzheimer disease
Alzheimer's dementia (HCC)	Early onset Alzheimer's dementia without behavioral disturbance (HCC)
Alzheimer's dementia with behavioral disturbance (HCC)	Early onset Alzheimer's disease with behavioral disturbance (HCC)
Alzheimer's dementia with behavioral disturbance, unspecified timing of dementia onset (HCC)	Family history of Alzheimer's disease
Alzheimer's dementia without behavioral disturbance (HCC)	Focal Alzheimer's disease (HCC) 'Late onset Alzheimer disease (HCC)
Alzheimer's dementia without behavioral disturbance, unspecified timing of dementia onset (HCC)	Late onset Alzheimer's disease with behavioral disturbance (HCC)
Alzheimer's dementia, late onset (HCC)	Late onset Alzheimer's disease without behavioral disturbance (HCC)
Alzheimer's dementia, late onset, with behavioral disturbance (HCC)	Major neurocognitive disorder due to Alzheimer's disease (HCC)
Alzheimer's disease (HCC)	Major neurocognitive disorder due to Alzheimer's disease, possible (HCC)
Alzheimer's disease of other onset	Major neurocognitive disorder due to Alzheimer's disease, probable, with behavioral disturbance (HCC)
Alzheimer's disease of other onset with behavioral disturbance (HCC)	Major neurocognitive disorder due to Alzheimer's disease, probable, without behavioral disturbance (HCC)
Alzheimer's disease of other onset without behavioral disturbance (HCC)	Major neurocognitive disorder due to Alzheimer's disease, with behavioral disturbance (HCC)
Alzheimer's disease with delirium (HCC)	Major neurocognitive disorder due to possible Alzheimer's disease (HCC)
Alzheimer's disease with early onset (CODE) (HCC)	Major neurocognitive disorder, due to Alzheimer's disease, with behavioral disturbance, mild (HCC)
Alzheimer's disease with early onset (HCC)	Major neurocognitive disorder, due to Alzheimer's disease, without behavioral disturbance, mild (HCC)
Alzheimer's disease with late onset (CODE) (HCC)	Major neurocognitive disorder, due to Alzheimer's disease, without behavioral disturbance, moderate (HCC)
Alzheimer's disease with late onset (HCC)	Major neurocognitive disorder, due to Alzheimer's disease, without behavioral disturbance, severe (HCC)
Alzheimer's disease with presenile onset (HCC)	Mild major neurocognitive disorder due to Alzheimer's disease with behavioral disturbance (HCC)
Alzheimer's disease, early onset (HCC)	Mild major neurocognitive disorder due to Alzheimer's disease without behavioral disturbance (HCC)
Alzheimer's disease, familial (HCC)	Mild neurocognitive disorder due to Alzheimer's disease (HCC)
Alzheimer's disease, focal onset (HCC)	Mild possible major neurocognitive disorder due to Alzheimer's disease (HCC)
Alzheimer's disease, unspecified (CODE) (HCC)	Mixed Alzheimer's and vascular dementia (HCC)
Alzheimer's disease, unspecified (HCC)	Mixed Alzheimer's and vascular dementia with behavior disturbances (HCC)
Alzheimer's type dementia (HCC)	Moderate major neurocognitive disorder due to Alzheimer's disease without behavioral disturbance (HCC)
Alzheimer's type dementia with late onset with behavioral disturbance (HCC)	Moderate probable major neurocognitive disorder due to Alzheimer's disease with behavioral disturbance
Alzheimer's type dementia with late onset without behavioral disturbance (HCC)	Other Alzheimer's disease (HCC)
Alzheimers disease (HCC)	Possible major neurocognitive disorder due to Alzheimer's disease
DAT (dementia Alzheimer type)	Primary degenerative dementia of Alzheimer type (HCC)
DAT (dementia of Alzheimer type) (HCC)	Primary degenerative dementia of the Alzheimer type, senile onset (HCC)
Dementia due to Alzheimer's disease (HCC)	Primary degenerative dementia of the Alzheimer type, senile onset, uncomplicated (HCC)
Dementia in Alzheimer's disease (HCC)	Primary degenerative dementia of the Alzheimer type, senile onset, with depression (HCC)
Dementia in Alzheimer's disease with delusions (HCC)	Probable major neurocognitive disorder due to Alzheimer's disease with behavioral disturbance
Dementia in Alzheimer's disease with depression (HCC)	Probable major neurocognitive disorder due to Alzheimer's disease without behavioral disturbance
Dementia in Alzheimer's disease with early onset (HCC)	Progressive aphasia in Alzheimer's disease (HCC)
Dementia in Alzheimer's disease with early onset with behavioral disturbance (HCC)	SDAT (senile dementia of Alzheimer's type) (HCC)
Dementia in Alzheimer's disease with early onset, without behavioral disturbance	Senile dementia of Alzheimer's type (HCC)
Dementia in Alzheimer's disease with late onset	Sporadic Alzheimer's disease (HCC)
Dementia of Alzheimer's type with behavioral disturbance (HCC)	
Dementia of Alzheimer's type, with early onset, with depressed mood (HCC)	
Dementia of the Alzheimer's type (HCC)	
Dementia of the Alzheimer's type with early onset with behavioral disturbance (HCC)	
Dementia of the Alzheimer's type with late onset without behavioral disturbance (HCC)	
Dementia of the Alzheimer's type without behavioral disturbance (HCC)	
Dementia of the Alzheimer's type, with late onset, uncomplicated (HCC)	
Dementia of the Alzheimer's type, with late onset, with delirium (HCC)	
Dementia of the Alzheimer's type, with late onset, with delusions (HCC)	
Dementia of the Alzheimer's type, with late onset, with depressed mood (HCC)	

Supplementary Table 2. UMAP Exclusion Terms

Table of diagnosis excluded in UMAP embedding. These terms contain the word

'Alzheimer'.

UCSF: Graph (>1%)		Number	Number	Avg Number	Network	Network	Characteristic	Clustering	Network	Network	Network	Connected	Components	Singlenets
		Nodes	Edges	Neighbors	Diameter	Radius	Path Length	Coefficient	density	heterogeneity	Centralization	Components	Singlenets	
ADDiagnosisNameAll		1056	27504	62.15	4	2	2.043	0.830	0.070	1.626	0.763	171	169	
ADDiagnosisNameFemale		962	25459	61.64	4	2	2.038	0.832	0.075	1.586	0.761	137	136	
ADDiagnosisNameMale		924	20102	52.90	4	2	2.057	0.823	0.070	1.633	0.739	164	162	
ADL3NameAll		483	23505	97.33	2	1	1.798	0.899	0.202	1.054	0.801	1	0	
ADL3NameFemale		452	21958	97.16	2	1	1.785	0.899	0.215	1.021	0.788	1	0	
ADL3NameMale		445	20099	90.33	2	1	1.797	0.899	0.203	1.046	0.800	1	0	
ADL2NameAll		165	7960	96.48	2	1	1.412	0.896	0.588	0.479	0.417	1	0	
ADL2NameFemale		160	7531	94.73	2	1	1.400	0.897	0.600	0.469	0.406	2	1	
ADL2NameMale		158	7257	91.86	2	1	1.415	0.892	0.585	0.481	0.420	1	0	
CopDiagnosisNameAll		421	2445	18.04	4	2	2.048	0.738	0.067	1.671	0.843	151	150	
CopDiagnosisNameFemale		167	2109	25.72	3	2	1.892	0.848	0.158	1.156	0.797	4	3	
CopDiagnosisNameMale		321	1417	13.43	4	2	2.078	0.681	0.064	1.717	0.815	111	110	
ConL3NameAll		318	5772	43.89	2	1	1.832	0.760	0.168	1.135	0.839	56	55	
ConL3NameFemale		190	5434	57.20	2	1	1.697	0.830	0.303	0.829	0.705	1	0	
ConL3NameMale		282	4195	37.46	3	2	1.837	0.750	0.168	1.125	0.835	59	58	
ConL2NameAll		150	3990	55.80	2	1	1.607	0.854	0.393	0.697	0.616	8	7	
ConL2NameFemale		122	3760	61.64	2	1	1.491	0.866	0.509	0.552	0.499	1	0	
ConL2NameMale		137	3200	48.48	2	1	1.630	0.862	0.370	0.726	0.640	6	5	
Mount Sinai: Graph (>1%)		Number	Number	Avg Number	Network	Network	Characteristic	Clustering	Network	Network	Network	Connected	Components	Singlenets
		Nodes	Edges	Neighbors	Diameter	Radius	Path Length	Coefficient	density	heterogeneity	Centralization	Components	Singlenets	
ADDiagnosisNameAll		483	1788	15.96	4	2	2.030	0.782	0.072	1.696	0.756	260	259	
ADDiagnosisNameFemale		482	1753	15.72	4	2	2.035	0.769	0.071	1.700	0.751	260	259	
ADDiagnosisNameMale		446	1034	12.16	4	2	2.084	0.722	0.072	1.674	0.700	277	276	
ADL3NameAll		348	10434	59.97	2	1	1.827	0.910	0.173	1.152	0.832	1	0	
ADL3NameFemale		352	10145	59.68	2	1	1.824	0.909	0.176	1.142	0.829	13	12	
ADL3NameMale		332	8162	52.32	2	1	1.832	0.905	0.168	1.166	0.837	21	20	
ADL2NameAll		141	4625	65.60	2	1	1.531	0.875	0.469	0.608	0.539	1	0	
ADL2NameFemale		141	4480	64.93	2	1	1.526	0.876	0.474	0.602	0.534	4	3	
ADL2NameMale		139	4037	59.37	2	1	1.560	0.878	0.440	0.642	0.569	4	3	
CopDiagnosisNameAll		461	13	3.25	3	2	1.607	0.558	0.464	0.527	0.524	454	453	
CopDiagnosisNameFemale		461	13	3.25	3	2	1.607	0.558	0.464	0.527	0.524	454	453	
CopDiagnosisNameMale		423	13	3.25	3	2	1.607	0.558	0.464	0.527	0.524	416	415	
ConL3NameAll		347	1038	17.16	2	1	1.857	0.788	0.143	1.267	0.871	231	230	
ConL3NameFemale		351	1038	17.16	2	1	1.857	0.788	0.143	1.267	0.871	213	212	
ConL3NameMale		331	980	16.47	3	2	1.863	0.780	0.140	1.280	0.867	61	60	
ConL2NameAll		141	1323	32.67	3	2	1.594	0.877	0.408	0.677	0.568	61	60	
ConL2NameFemale		141	1323	32.67	3	2	1.594	0.877	0.408	0.677	0.568	61	60	
ConL2NameMale		139	1290	31.85	3	2	1.606	0.865	0.398	0.690	0.566	59	58	


UCSF Comparison	Nodes	Mann Whitney U Test	Avg Shortest Path Length	Betweenness Centrality	Closeness Centrality	Clustering Coefficient	Degree	Eccentricity	Neighborhood Connectivity	Number Undirected Edges	Stress Centrality	Topological Coefficient
Alzheimer vs Control: Diagnosis Name	All Nodes	Stat	2.68E+05	2.46E+05	2.63E+05	2.73E+05	3.07E+05	3.22E+05	3.73E+05	3.07E+05	2.56E+05	2.81E+05
	pval	3.75E-10	9.15E-05	2.31E-08	1.07E-12		1.02E-30	6.87E-48	1.58E-93	1.02E-30	2.48E-08	6.20E-16
	Δmean	3.96E-01	-1.52E-03	9.88E-02	2.20E-01		4.05E+01	1.01E+00	2.57E+02	4.05E+01	1.17E+04	1.35E-01
	Singletons Removed	Stat	1.23E+05	8.88E+03	1.18E+05	8.99E+04	1.61E+05	1.76E+05	2.28E+05	1.61E+05	1.89E+04	9.85E+04
	pval	6.05E-01	4.64E-11	6.05E-01	7.51E-01	1.22E-17	3.06E-42	4.30E-110	1.22E-17	1.31E-02	5.76E-02	
	Δmean	-7.26E-03	-9.16E-03	2.03E-03	1.81E-02	4.40E+01	4.97E-01	2.76E+02	4.40E+01	3.19E+04	3.63E-02	
Alzheimer vs Control: L3 Name	All Nodes	Stat	8.30E+04	8.19E+04	9.71E+04	1.02E+05	1.10E+05	9.02E+04	1.39E+05	1.10E+05	8.70E+04	1.13E+05
	pval	5.19E-02	7.44E-02	2.16E-10	3.00E-17	2.15E-25	6.25E-21	2.69E-85	2.15E-25	3.50E-04	4.21E-29	
	Δmean	2.83E-01	-9.79E-04	1.08E-01	2.70E-01	6.10E+01	3.47E-01	1.76E+02	6.10E+01	6.20E+03	2.50E-01	
	Singletons Removed	Stat	5.65E+04	1.03E+04	7.06E+04	5.77E+04	8.36E+04	6.36E+04	1.13E+05	8.36E+04	1.55E+04	6.79E+04
	pval	0.0121	0.0274	1.21E-02	1.03E-01	9.42E-13	6.64E-01	4.02E-69	9.42E-13	4.96E-05	2.53E-08	
	Δmean	-3.44E-02	-3.70E-03	1.27E-02	1.80E-02	5.34E+01	1.73E-03	1.49E+02	5.34E+01	1.31E+04	1.00E-01	
Alzheimer vs Control: L2 Name	All Nodes	Stat	8.40E+03	1.39E+04	1.75E+04	1.26E+04	1.88E+04	1.29E+04	2.06E+04	1.88E+04	1.50E+04	1.72E+04
	pval	8.40E-07	5.70E-02	2.06E-10	7.73E-01	1.51E-15	3.52E-02	3.65E-24	1.51E-15	9.45E-04	2.48E-09	
	Δmean	-1.20E-01	-1.58E-03	1.23E-01	8.24E-02	4.33E+01	8.79E-02	3.31E+01	4.33E+01	7.29E+02	1.39E-01	
	Singletons Removed	Stat	7.24E+03	3.93E+03	1.64E+04	1.08E+04	1.77E+04	1.17E+04	1.94E+04	1.77E+04	5.03E+03	1.54E+04
	pval	5.14E-09	0.11	5.14E-09	0.362	5.46E-14	6.51E-01	1.64E-22	5.46E-14	2.07E-01	3.12E-07	
	Δmean	-1.95E-01	-4.17E-03	9.26E-02	1.80E-02	4.07E+01	-5.13E-03	2.85E+01	4.07E+01	4.30E+02	8.91E-02	
Female AD vs Male AD: Diagnosis Name	All Nodes	Stat	4.57E+05	4.69E+05	4.88E+05	4.73E+05	4.85E+05	3.41E+05	5.22E+05	4.85E+05	4.72E+05	4.78E+05
	pval	5.15E-01	7.16E-01	6.35E-02	4.96E-01	9.92E-02	3.39E-31	2.96E-06	9.92E-02	4.90E-01	2.93E-01	
	Δmean	1.98E-02	-8.89E-05	1.02E-02	1.69E-02	8.26E+00	-2.87E-01	4.19E+01	8.26E+00	2.75E+03	1.39E-02	
	Singletons Removed	Stat	3.09E+05	5.33E+04	3.39E+05	2.68E+05	3.37E+05	1.92E+05	3.74E+05	3.37E+05	5.67E+04	2.73E+05
	pval	1.01E-01	4.56E-01	1.01E-01	9.79E-01	1.71E-01	1.10E-73	9.98E-08	1.71E-01	5.32E-01	5.68E-01	
	Δmean	-1.50E-02	-3.69E-04	2.79E-03	1.27E-03	8.82E+00	-4.06E-01	4.32E+01	8.82E+00	6.85E+03	6.75E-03	
Female AD vs Male AD: L3 Name	All Nodes	Stat	1.05E+05	1.04E+05	1.04E+05	1.05E+05	1.07E+05	1.04E+05	1.13E+05	1.07E+05	1.05E+05	1.06E+05
	pval	9.12E-01	9.13E-01	9.12E-01	9.61E-01	5.28E-01	9.74E-01	3.08E-02	5.28E-01	9.59E-01	7.47E-01	
	Δmean	2.59E-03	-7.91E-05	-7.28E-04	-8.94E-04	3.28E+00	1.05E-04	1.36E+01	3.28E+00	9.47E+02	-2.65E-04	
	Singletons Removed	Stat	1.05E+05	2.01E+04	1.04E+05	1.03E+05	1.07E+05	1.04E+05	1.13E+05	1.07E+05	2.07E+04	1.04E+05
	pval	0.912	0.461	9.12E-01	9.70E-01	5.28E-01	9.74E-01	3.08E-02	5.28E-01	8.03E-01	7.53E-01	
	Δmean	2.59E-03	-2.17E-04	-7.28E-04	-1.29E-03	3.28E+00	1.05E-04	1.36E+01	3.28E+00	1.95E+03	-5.36E-04	
Female AD vs Male AD: L2 Name	All Nodes	Stat	1.24E+04	1.27E+04	1.29E+04	1.27E+04	1.31E+04	1.26E+04	1.36E+04	1.31E+04	1.28E+04	1.29E+04
	pval	7.59E-01	9.08E-01	7.59E-01	9.74E-01	5.62E-01	9.92E-01	2.61E-01	5.62E-01	8.70E-01	7.35E-01	
	Δmean	-7.12E-03	-7.87E-05	3.60E-03	5.89E-03	2.30E+00	1.58E-04	2.10E-00	2.30E+00	6.22E+01	3.46E-03	
	Singletons Removed	Stat	1.24E+04	5.31E+03	1.29E+04	1.27E+04	1.31E+04	1.26E+04	1.36E+04	1.31E+04	5.35E+03	1.29E+04
	pval	7.59E-01	0.429	7.59E-01	0.974	5.62E-01	0.992	2.61E-01	5.62E-01	0.48	7.35E-01	
	Δmean	-7.12E-03	-3.26E-04	3.60E-03	5.89E-03	2.30E+00	1.58E-04	2.10E-00	2.30E+00	-2.47E+02	3.46E-03	
Female: AD vs Control: Diagnosis Name	All Nodes	Stat	2.47E+05	2.23E+05	2.34E+05	2.47E+05	2.78E+05	2.49E+05	3.40E+05	2.78E+05	2.33E+05	2.55E+05
	pval	3.15E-11	1.16E-04	1.98E-06	6.28E-12	8.80E-29	3.89E-18	5.56E-91	8.80E-29	4.00E-08	3.53E-15	
	Δmean	3.93E-01	-1.55E-03	9.58E-02	2.18E-01	3.99E+01	6.46E-01	2.45E+02	3.99E+01	1.14E+04	1.36E-01	
	Singletons Removed	Stat	1.17E+05	8.17E+03	1.04E+05	8.21E+04	1.47E+05	1.19E+05	2.10E+05	1.47E+05	1.74E+04	9.03E+04
	pval	1.53E-01	1.32E-10	1.53E-01	7.09E-01	1.68E-16	2.64E-04	1.15E-107	1.68E-16	1.43E-02	5.98E-02	
	Δmean	-1.64E-03	-9.37E-03	1.03E-04	1.76E-02	4.33E+01	8.01E-02	2.62E+02	4.33E+01	3.09E+04	3.67E-02	
Female: AD vs Control: L3 Name	All Nodes	Stat	7.79E+04	7.70E+04	9.01E+04	9.57E+04	1.02E+05	8.41E+04	1.30E+05	1.02E+05	8.16E+04	1.05E+05
	pval	5.75E-02	7.26E-02	3.32E-09	3.11E-16	3.67E-23	1.91E-19	1.25E-80	3.67E-23	4.57E-04	2.62E-27	
	Δmean	2.72E-01	-1.00E-03	1.03E-01	2.67E-01	3.32E+01	1.67E-01	5.77E+01	5.77E+01	5.77E+03	2.46E-01	
	Singletons Removed	Stat	5.40E+04	9.75E+03	6.63E+04	5.42E+04	7.85E+04	6.02E+04	1.06E+05	7.85E+04	1.44E+04	6.36E+04
	pval	0.02297	0.023	2.30E-02	1.23E-01	1.05E-11	6.68E-01	1.26E-55	1.05E-11	3.64E-04	9.73E-08	
	Δmean	-3.09E-02	-3.80E-03	1.15E-02	1.81E-02	5.04E-01	1.75E-03	1.42E-02	5.04E-01	1.19E+04	9.75E-02	
Female: AD vs Control: L2 Name	All Nodes	Stat	7.93E+03	1.29E+04	1.64E+04	1.22E+04	1.76E+04	1.21E+04	1.92E+04	1.76E+04	1.39E+04	1.64E+04
	pval	1.25E-06	1.10E-01	1.13E-09	5.29E-01	1.39E-14	6.37E-02	3.75E-22	1.39E-14	2.95E-03	8.95E-10	
	Δmean	-1.25E-01	-1.58E-03	1.18E-01	8.53E-02	4.07E-01	6.11E-01	4.82E-03	6.11E-01	5.77E+03	1.42E-01	
	Singletons Removed	Stat	6.97E+03	3.97E+03	1.54E+04	1.04E+04	1.67E+04	1.11E+04	1.82E+04	1.67E+04	5.00E+03	1.47E+04
	pval	1.70E-08	0.253	1.70E-08	0.573	2.92E-13	0.645	9.58E-21	2.92E-13	0.106	1.27E-07	
	Δmean	-1.91E-01	-3.84E-03	9.11E-02	1.91E-02	3.84E-01	-5.36E-03	2.65E+01	3.84E+01	4.35E+02	9.01E-02	
Male: AD vs Control: Diagnosis Name	All Nodes	Stat	1.76E+05	1.67E+05	1.81E+05	1.91E+05	2.11E+05	2.16E+05	2.52E+05	2.11E+05	1.74E+05	1.94E+05
	pval	1.84E-05	1.18E-03	2.82E-07	5.34E-13	3.46E-26	3.29E-34	1.28E-71	3.46E-26	9.63E-07	2.09E-14	
	Δmean	3.44E-01	-2.21E-03	8.95E-02	2.38E-01	3.47E+01	9.30E-01	2.19E+02	3.47E+01	9.11E+03	1.42E-01	
	Singletons Removed	Stat	7.94E+04	6.72E+03	8.42E-04	5.83E+04	1.15E+05	1.19E+05	1.56E+05	1.15E+05	1.43E+04	6.18E+04
	pval	5.14E-01	5.87E-07	5.14E-01	6.58E-01	2.12E-19	8.54E-33	8.81E-91	2.12E-19	4.09E-05	1.02E-01	
	Δmean	-2.25E-02	-1.24E-02	5.42E-03	2.49E-02	3.92E+01	4.96E-01	2.43E+02	3.92E+01	2.60E+04	3.46E-02	
Male: AD vs Control: L3 Name	All Nodes	Stat	6.90E+04	6.68E+04	8.31E+04	8.75E+04	9.24E+04	5.06E+04	1.18E+05	9.24E+04	7.20E+04	9.50E+04
	pval	3.34E-02	1.31E-01	5.52E-13	1.91E-20	4.43E-26	1.11E-09	8.58E-88	4.43E-26	3.40E-04	9.71E-31	
	Δmean	3.35E-01	-1.19E-03	1.28E-01	3.03E-01	6.11E-01	4.82E-03	1.77E-02	6.11E-01	5.27E+03	2.74E-01	
	Singletons Removed	Stat	4.31E+04	8.47E+03	5.72E+04	4.67E+04	6.65E+04	2.47E+04	9.23E+04	6.65E+04	1.36E+04	5.42E+04
	pval	0.00297	0.0189	2.97E-03	2.26E-02	5.72E-12	6.79E-61	1.56E-70	5.72E-12	1.35E-06	1.52E-08	
	Δmean	-4.15E-02	-4.27E-03	1.46E-03	2.35E-02	5.34E-01	-5.09E-01	1.50E-02	5.34E-01	1.12E-04	1.11E-01	
Male: AD vs Control: L2 Name	All Nodes	Stat	6.83E+03	1.17E+04	1.56E+04	1.11E+04	1.69E+04	1.12E+04	1.88E+04	1.69E+04	1.29E+04	1.49E+04
	pval	4.73E-08	2.10E-01	6.05E-11	7.50E-01	1.41E-16	9.67E-02	1.55E-27	1.41E-16	3.31E-03	2.52E-08	
	Δmean	-1.56E-01	-2.01E-03	1.24E-01	6.13E-02	4.51E-01	6.76E-02	3.51E+01	4.51E+01	4.51E+01	8.48E+02	1.29E-01
	Singletons Removed	Stat	6.04E+03	3.88E+03	4.48E+04	9.94E+03	1.					

Mount Sinai Comparison	Nodes	Mann Whitney U Test	Avg Shortest Path Length	Betweenness Centrality	Closeness Centrality	Clustering Coefficient	Degree	Eccentricity	Neighborhood Connectivity	Number Undirected Edges	Stress Centrality	Topological Coefficient
Alzheimer vs Control: Diagnosis Name	All Nodes	Stat	1.62E+05	1.28E+05	1.60E+05	1.55E+05	1.61E+05	1.62E+05	1.62E+05	1.61E+05	1.29E+05	1.55E+05
		pval	6.92E-57	9.38E-17	2.49E-54	1.21E-48	1.91E-56	6.59E-58	1.48E-57	1.91E-56	3.27E-17	1.27E-47
		Δmean	9.13E-01	3.95E-04	2.20E-01	3.53E-01	7.35E+00	1.37E+00	5.33E+01	7.35E+00	4.23E+02	2.08E-01
	Singletons Removed	Stat	1.49E+03	1.20E+01	3.06E+02	7.93E+02	1.28E+03	1.47E+03	1.79E+03	1.28E+03	2.68E+02	3.96E+02
		pval	1.55E-03	1.98E-03	1.55E-03	1.04E-01	3.82E-02	3.72E-09	1.56E-06	3.82E-02	2.04E-02	1.74E-01
		Δmean	4.23E-01	-1.89E-01	-1.49E-01	1.49E-01	1.27E+01	6.79E-01	1.10E+02	1.27E+01	2.57E+03	-1.13E-01
Alzheimer vs Control: L3 Name	All Nodes	Stat	9.83E+04	9.77E+04	1.01E+05	1.02E+05	1.09E+05	9.98E+04	1.19E+05	1.09E+05	7.97E+04	1.05E+05
		pval	4.40E-48	4.50E-17	2.23E-55	6.00E-62	4.78E-78	1.82E-74	1.90E-113	4.78E-78	9.06E-21	4.25E-66
		Δmean	1.18E+00	-1.21E-04	3.65E-01	6.35E-01	5.40E+01	1.30E+00	1.95E+02	5.40E+01	3.59E+03	4.59E-01
	Singletons Removed	Stat	1.96E+04	1.87E+03	2.25E+04	1.82E+04	3.04E+04	2.11E+04	4.06E+04	3.04E+04	3.82E+03	2.10E+04
		pval	0.263	0.000503	2.63E-01	8.41E-01	4.24E-13	7.67E-01	2.67E-52	4.24E-13	2.76E-03	3.08E-02
		Δmean	-2.98E-02	-1.61E-02	1.02E-02	1.04E-02	4.28E+01	2.52E-03	1.45E+02	4.28E+01	7.72E+03	5.50E-02
Alzheimer vs Control: L2 Name	All Nodes	Stat	1.34E+04	1.20E+04	1.49E+04	1.41E+04	1.69E+04	1.35E+04	1.96E+04	1.69E+04	1.28E+04	1.49E+04
		pval	2.63E-07	6.47E-04	3.71E-13	3.72E-10	1.79E-24	3.02E-12	1.69E-45	1.79E-24	1.92E-06	4.61E-13
		Δmean	6.15E-01	-5.00E-04	3.05E-01	3.71E-01	4.68E+01	7.80E-01	7.09E+01	4.68E+01	1.43E+03	3.33E-01
	Singletons Removed	Stat	4.99E+03	1.27E+03	6.43E+03	5.63E+03	8.44E+03	5.07E+03	1.11E+04	8.44E+03	2.09E+03	6.41E+03
		pval	1.18E-01	0.15	1.18E-01	0.856	3.22E-09	0.00012	6.39E-32	3.22E-09	0.00077	0.128
		Δmean	-6.30E-02	-7.58E-03	2.93E-02	-1.83E-03	3.29E+01	-1.13E-01	4.71E+01	3.29E+01	2.31E+03	3.40E-02
Female AD vs Male AD: Diagnosis Name	All Nodes	Stat	1.14E+05	1.09E+05	1.19E+05	1.17E+05	1.18E+05	1.15E+05	1.24E+05	1.18E+05	1.09E+05	1.16E+05
		pval	8.97E-02	5.42E-01	2.08E-03	5.16E-03	4.75E-03	3.29E-02	8.66E-06	4.75E-03	4.39E-01	1.02E-02
		Δmean	1.47E-01	-2.93E-04	4.45E-02	8.06E-02	2.64E+00	2.25E-01	2.12E+01	2.64E+00	1.52E+02	4.46E-02
	Singletons Removed	Stat	1.64E+04	1.99E+03	2.15E+04	1.44E+04	2.05E+04	1.78E+04	2.65E+04	2.05E+04	2.40E+03	1.37E+04
		pval	2.31E-02	6.72E-02	2.31E-02	2.50E-01	1.52E-01	4.96E-02	1.26E-11	1.52E-01	9.25E-01	8.51E-01
		Δmean	-4.90E-02	-3.85E-03	1.03E-02	2.26E-02	3.56E+00	-6.38E-02	3.12E+01	3.56E+00	7.35E+02	3.32E-03
Female AD vs Male AD: L3 Name	All Nodes	Stat	5.94E+04	5.86E+04	6.06E+04	6.06E+04	6.26E+04	5.98E+04	6.77E+04	6.26E+04	5.93E+04	6.14E+04
		pval	7.17E-01	9.39E-01	4.12E-01	3.51E-01	1.03E-01	1.60E-01	3.56E-04	1.03E-01	7.02E-01	2.43E-01
		Δmean	4.04E-02	-1.67E-04	1.72E-02	2.79E-02	8.47E+00	4.96E-02	2.42E+01	8.47E+00	7.39E+02	2.51E-02
	Singletons Removed	Stat	5.24E+04	9.11E+03	5.36E+04	5.34E+04	5.57E+04	5.29E+04	6.07E+04	5.57E+04	9.81E+03	5.42E+04
		pval	8.06E-01	6.18E-01	8.06E-01	8.18E-01	6.23E-01	6.15E-01	1.36E-03	2.63E-01	5.75E-01	5.84E-01
		Δmean	-7.80E-03	-5.46E-04	2.77E-03	1.46E-03	7.36E+00	-2.68E-03	1.97E+01	7.36E+00	1.67E+03	6.90E-03
Female AD vs Male AD: L2 Name	All Nodes	Stat	9.16E+03	9.68E+03	1.04E+04	9.94E+03	1.06E+04	9.80E+03	1.07E+04	1.06E+04	9.79E+03	1.03E+04
		pval	0.348	0.853	0.344	0.824	0.251	0.984	0.206	0.251	0.991	0.446
		Δmean	-0.033	-0.000305	0.016	-0.00158	5.46	0.000816	3.44	5.46	1.58E+02	0.0148
	Singletons Removed	Stat	8.74E+03	2.79E+03	1.00E+04	9.52E+03	1.02E+04	9.39E+03	1.02E+04	1.02E+04	2.90E+03	9.90E+03
		pval	0.33	0.518	0.33	0.821	0.238	0.991	0.193	0.238	0.278	0.434
		Δmean	-0.0342	-0.000165	0.0161	-0.00189	5.56	0.000213	3.49	5.56	4.69E+02	0.0149
Female: AD vs Control: Diagnosis Name	All Nodes	Stat	1.61E+05	1.28E+05	1.60E+05	1.54E+05	1.61E+05	1.61E+05	1.61E+05	1.61E+05	1.28E+05	1.54E+05
		pval	1.05E-56	2.60E-16	4.05E-04	1.67E-47	3.26E-56	1.07E-57	2.35E-57	3.26E-56	9.41E-17	1.74E-46
		Δmean	9.14E-01	4.12E-04	2.19E-01	3.46E-01	7.22E+00	1.37E+00	5.27E+01	7.22E+00	4.13E+02	2.03E-01
	Singletons Removed	Stat	1.49E+03	1.20E+01	2.96E+02	7.81E+02	1.26E+03	1.46E+03	1.78E+03	1.26E+03	2.59E+02	3.80E+02
		pval	1.35E-03	2.04E-03	1.35E-03	9.68E-02	4.74E-02	3.99E-09	1.58E-06	4.74E-02	2.27E-02	1.57E-01
		Δmean	4.28E-01	-1.89E-01	-1.51E-01	1.49E-01	1.25E+01	6.79E-01	1.10E+02	1.25E+01	2.57E+03	-1.17E-01
Female: AD vs Control: L3 Name	All Nodes	Stat	9.85E+04	7.88E+04	1.02E+05	1.03E+05	1.09E+05	1.00E+05	1.19E+05	1.09E+05	8.07E+04	1.05E+05
		pval	3.74E-44	2.28E-16	5.53E-52	1.98E-57	1.26E-72	7.58E-67	7.20E-105	1.26E-72	8.06E-20	6.21E-62
		Δmean	1.12E+00	-1.28E-04	3.50E-01	6.07E-01	5.17E+01	1.24E+00	1.83E+02	5.17E+01	3.40E+03	4.42E-01
	Singletons Removed	Stat	1.89E+04	1.85E+03	2.22E+04	1.78E+04	2.97E+04	2.06E+04	3.95E+04	2.97E+04	3.73E+03	2.06E+04
		pval	0.197	0.000661	1.97E-01	8.13E-01	1.36E-13	7.82E-01	2.38E-51	3.61E-13	3.23E-03	2.55E-02
		Δmean	-3.31E-02	-1.60E-02	1.14E-02	9.48E-03	4.25E+01	2.38E-03	1.41E+02	4.25E+01	7.53E+03	5.71E-02
Female: AD vs Control: L2 Name	All Nodes	Stat	1.32E+04	1.19E+04	1.47E+04	1.39E+04	1.66E+04	1.33E+04	1.92E+04	1.66E+04	1.27E+04	1.47E+04
		pval	1.65E-06	1.52E-03	2.38E-12	1.99E-09	7.39E-23	8.21E-11	2.70E-42	7.39E-23	7.09E-06	3.44E-12
		Δmean	5.78E-01	-5.37E-04	2.94E-01	3.53E-01	4.48E+01	7.38E-01	6.69E+01	4.48E+01	1.34E+03	3.19E-01
	Singletons Removed	Stat	4.83E+03	1.26E+03	6.34E+03	5.54E+03	8.27E+03	4.96E+03	1.09E+04	8.27E+03	2.06E+03	6.31E+03
		pval	9.56E-02	0.239	9.56E-02	0.911	3.08E-09	0.000136	3.16E-31	3.08E-09	0.000274	0.112
		Δmean	-6.84E-02	-7.35E-03	3.19E-02	-1.29E-03	3.23E+01	-1.13E-01	4.52E+01	3.23E+01	2.26E+03	3.65E-02
Male: AD vs Control: Diagnosis Name	All Nodes	Stat	1.29E+05	1.07E+05	1.28E+05	1.23E+05	1.29E+05	1.29E+05	1.29E+05	1.29E+05	1.07E+05	1.23E+05
		pval	2.85E-40	6.02E-13	3.40E-38	1.97E-32	1.05E-39	1.36E-40	9.84E-41	1.05E-39	2.27E-13	8.08E-32
		Δmean	7.64E-01	5.47E-04	1.74E-01	2.65E-01	4.58E+00	1.14E+00	3.15E+01	4.58E+00	2.61E+02	1.57E-01
	Singletons Removed	Stat	1.15E+03	1.00E+01	2.07E+02	5.52E+02	8.94E+02	1.13E+03	1.36E+03	8.94E+02	2.36E+02	2.91E+02
		pval	9.02E-04	2.24E-03	9.02E-04	1.70E-01	1.32E-01	1.93E-06	1.82E-06	1.32E-01	3.76E-03	1.98E-01
		Δmean	4.77E-01	-1.85E-01	-1.61E-01	1.26E-01	8.91E+00	7.43E-01	7.83E+01	8.91E+00	1.84E+03	-1.20E-01
Male: AD vs Control: L3 Name	All Nodes	Stat	1.29E+05	1.07E+05	1.28E+05	1.23E+05	1.29E+05	1.29E+05	1.29E+05	1.29E+05	1.07E+05	1.23E+05
		pval	2.85E-40	6.02E-13	3.40E-38	1.97E-32	1.05E-39	1.36E-40	9.84E-41	1.05E-39	2.27E-13	8.08E-32
		Δmean	7.64E-01	5.47E-04	1.74E-01	2.65E-01	4.58E+00	1.14E+00	3.15E+01	4.58E+00	2.61E+02	1.57E-01
	Singletons Removed	Stat	1.15E+03	1.00E+01	2.07E+02	5.52E+02	8.94E+02	1.13E+03	1.36E+03	8.94E+02	2.36E+02	2.91E+02
		pval	9.00092	0.00224	9.02E-04	1.70E-01	1.32E-01	1.93E-06	1.82E-06	1.32E-01	3.76E-03	1.98E-01
		Δmean	4.77E-01	-1.85E-01	-1.61E-01	1.26E-01	8.91E+00	7.43E-01	7.83E+01	8.91E+00	1.84E+03	-1.20E-01
Male: AD vs Control: L2 Name	All Nodes	Stat	1.30E+04	1.17E+04	1.40E+04	1.35E+04	1.58E+04	1.28E+04	1.85E+04	1.58E+04	1.24E+04	1.41E+04
		pval	6.41E-07	8.24E-04	8.73E-11	4.08E-09	4.30E-20	8.55E-10	5.46E-40	4.30E-20	4.95E-06	3.24E-11
		Δmean	5.91E-01	-3.78E-04	2.75E-01	3.55E-01	3.95E-01	7.12E-01	6.31E-01	3.95E-01	1.18E+03	3.08E-01
	Singletons Removed	Stat	5.00E+03	1.23E+03	6.01E+03	5.37E+03	7.81E+03	4.82E+03	1.05E+04	7.81E+03	1.96E+03	5.97E+03
		pval	2.61E-01	0.0909	2.61E-01	0.872	2.80E-07	5.81E-05	5.09E-29	2.80E-07	0.00993	0.232</

Supplementary Table 3. All Diagnosis Network Metrics


An attached excel sheet with 3 tabs. **Tab 1:** Diagnosis Networks are created with nodes representing a diagnostic category or diagnosis shared among >1% of patients in a group, and edges representing >1% of co-diagnosis in a group. **Tab 2 (UCSF) and 3 (Mount Sinai):** Network metrics are computed for nodes in each network, and the distribution of metrics are compared between networks. Comparisons are performed with and without the removal of singletons (single nodes with no neighbors). A Mann-Whitney U-test is performed to compare the distribution of each network metric, with colors based upon p-value cutoff. The mean difference in metric between comparison groups is also shown.

Supplementary Figures



Supplementary Figure 1. Demographic correlation across UMAP principal components.

- The top two graphs show the UMAP of AD and control cohorts at UCSF, colored by deceased status (left) and estimated age (right). The middle graphs show distribution of deceased status among the two UMAP components, which are compared with a two-sided Mann-Whitney U-Test. The bottom graphs show estimated age across the two UMAP components, with marginal distributions shown on the sides. A regression line is plotted, and a Pearson's R correlation test is performed.
- The same UMAP plots are shown as in a, but for Mount Sinai.




Supplementary Figure 2. Comorbidity Enrichment Analysis identifies enriched diagnosis in Patients with AD vs. Controls and Sex-Specific Enrichments at Mount Sinai.

- Volcano plot for Level 2 categories (top) and full diagnosis names (bottom) compared between AD and control cohorts using two-sided Fisher Exact or Chi-Squared test. P-value cutoff is Bonferroni corrected at 0.05 with \log_2 odds ratio cutoff at 1 for AD enriched (pink)


and remaining significant diagnoses in blue.

- b. Above, a Manhattan plot with full diagnosis names colored by ICD-10-CM categories with significance determined by two-sided Fisher Exact or Chi Square Test with Bonferroni-corrected p-value cutoff of 0.05. Bottom, percentage of diagnosis in each ICD-10-CM category that is significant.
- c. Full diagnosis names compared between patients with AD and controls within each sex. The log of the odds ratio is plotted on the axis, and points are colored by significance (two-sided Fisher Exact or Chi Square test with Bonferroni-corrected p-value cutoff of 0.05).
- d. Miami plot of the diagnosis names grouped by sex and ICD-10-CM categories.



Supplementary Figure 3. Medication Enrichment Analysis identifies Enriched Medications between AD and Control Cohorts.

- Volcano plot for generic medication names compared between patients with AD and controls using two-sided Fisher Exact or Chi-Squared Test. P-value cutoff is Bonferroni-corrected at 0.05 with odds ratio cutoff at 2 for AD enriched (pink) or 1/2 for controlled enriched (green). Remaining significant diagnoses are in blue.
- Log-log plot of generic medication names compared between patients with AD and controls within each sex. The log of the odds ratio for each sex is plotted on the axis, with points colored by significance (Bonferroni-corrected p-value of 0.05) if female only (red), male only (blue), or both (black).



Supplementary Figure 4. Stratifying by AD status and sex allows identification of lab trends between groups.

a. Heatmap of lab values filtered on significance at UCSF in AD vs control comparison across

sex-specific groups. Labs are clustered with light blue lines representing significant cluster breaks (FWER corrected p-value 0.05). Text color represents significant labs among females only (pink), or significant between patients with AD vs control patients (black).

Heatmap colors represent z-score of the average median value across the 4 groups.

- b. Heatmap of lab values filtered on significance at Mount Sinai in AD vs control comparison across sex-specific groups. Labs are clustered with light blue lines representing significant cluster breaks (FWER corrected p-value 0.05). Text color represents significant labs among males only (green), or significant between patients with AD vs control patients (black).
- Heatmap colors represent z-score of the average median value across the 4 groups.
- c. Comparison of z-scored lab values between UCSF and Mount Sinai showing significant correlations within each AD/sex-stratified groups. Female control: Spearman $\rho = 0.45$, p-value < 0.001; Male control: 0.46, p-value < 0.001; Females with AD: 0.59, p-value < 1e-5; Males with AD: 0.64, p-value < 1e-5.